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Propylisopropylacetic acid (PIA) is a constitutional isomer of valproic acid (VPA). It has previously been
found to be a weak antiepileptic, but in common with mood stabilizers, causes inositol depletion and
growth cone spreading, suggesting the basis of a new series of mood stabilizers. To assess this possibility,
we have compared the effects of racemic (R,S)-PIA and its individual enantiomers to those of the mood
stabilizers lithium (Liþ), VPA and carbamazepine (CBZ). Unlike Liþ and VPA, but in commonwith CBZ and
(R,S)-PIA, neither (R)-PIA nor (S)-PIA enantiomer induces T-cell factor (TCF)-mediated gene expression.
However, as seen for other mood stabilizers, both enantiomers are potent inducers of growth cone
spreading. To investigate the mechanism for these effects, we examined changes in the actin cytoskel-
eton following drug treatment with Liþ, VPA, CBZ, (R,S)-PIA or its individual enantiomers. All exhibit a re-
distribution of F-actin to the growth cone periphery, a feature of spread growth cones. (R,S)-PIA has the
strongest effect as it also elevates F-actin polymerization at the cell periphery. This change in the actin
cytoskeleton is associated with a substantial increase in F-actin-rich protrusions on the surface of the
growth cone and in its close vicinity. These results demonstrate an effect of (R,S)-PIA on the neuronal
actin cytoskeleton shared in common with other mood stabilizers, and suggest a potential to induce
structural changes within the CNS.
 2009 Elsevier Ltd. Open access under CC BY license.1. Introduction
Despite an intense research effort, the development of more
potent and effective mood stabilizers has been slow. A major
barrier to progress is our lack of molecular understanding of the
mechanisms that underlie both the origin and the treatment of
bipolar disorder. As no available models can replicate both aspects
of mania and depression and therefore fail to mimic the hallmark of
the illness, alternative approaches are being explored for identi-
fying potential new mood stabilizers (Cryan and Slattery, 2007;
Machado-Vieira et al., 2004).
Williams et al. (2002) have developed a cellular model based on
the regeneration of sensory neurons (Williams et al., 2002). Here,
cultured explants of rat dorsal root ganglions (DRGs) are allowed to
regenerate axons. The growth cones at the termini of these
regenerating axons are sensitive to drug treatment, and the moodx: þ44 2920 874116.
).
Y license.stabilizers lithium (Liþ), valproic acid (VPA) or carbamazepine (CBZ)
induce an increase in growth cone spreading. This change in
morphology can be measured by calculation of growth cone spread
areas. Using this as a bioassay, we recently found that PIA,
a constitutional isomer of VPA, also induces growth cone spreading
(Shimshoni et al., 2007a). This raises the question of themechanism
of this and other mood stabilizers on growth cone behaviour.
Both Liþ and VPAmimic the effects of Wnt signaling by inducing
T-cell factor (TCF)-mediated gene expression (Gould et al., 2007;
Lucas et al., 1998; Phiel et al., 2001). As Wnt signaling is crucial for
the development of the CNS and is directly involved in neuro-
genesis and neuronal differentiation, it remains a potential target of
mood stabilizers (Lucas et al., 1998). Liþ stimulates Wnt signaling
via inhibition the downstream protein kinase glycogen synthase
kinase-3 (GSK-3) leading to increased b-catenin protein concen-
trations (Harwood and Agam, 2003; Klein and Melton, 1996; Ryves
and Harwood, 2001). Elevated b-catenin binds to and activates the
transcription factor TCF to control gene expression. In some, but not
all cellular systems, VPA can indirectly increase b-catenin expres-
sion via inhibition of histone deacetylase (HDAC) (Phiel et al., 2001;
J.A. Shimshoni et al. / Neuropharmacology 56 (2009) 831–837832Ryves et al., 2005), again stimulating TCF-mediated gene
expression.
There are a number of problems with this hypothesis. First, GSK-
3 mediates changes in microtubule dynamics through phosphory-
lation of microtubule associated proteins, such as MAP1B and tau
(Lovestone et al., 1999; Owen and Gordon-Weeks, 2003; Sang et al.,
2001). However, whilst Liþ treatment or Wnt stimulation causes
growth cone spreading with an associated change in microtubule
morphology, this is not the case for the alternative mood stabilizers
VPA and CBZ (Williams et al., 2002). These drugs cause the same
degree of growth cone spreading, but no major change of the
microtubule cytoskeleton. Second, previous results have shown
that CBZ does not increase b-catenin expression, but is a potent
inducer of growth cone spreading (Ryves et al., 2005; Williams
et al., 2002). Third, (R,S)-PIA induces growth cone spreading, but
has no effect on TCF-mediated gene expression (Shimshoni et al.,
2007a). These results argue against a common mechanism for all
mood stabilizers on either Wnt signaling or regulation of micro-
tubule dynamics within the neuronal growth cone.
In contrast, the effects of all drugs, Liþ, VPA, CBZ and (R,S)-PIA,
can be reversed by addition of myo-inositol, suggesting a mecha-
nism via inositol depletion. This mechanism was ﬁrst suggested by
Berridge et al. (1989) to explain the effects of lithium on inositol-
1,4,5-triphosphate (InsP3) mediated signaling. Li
þ is a non-
competitive inhibitor of inositol-monophosphatase (IMPase)
(Atack et al., 1995; Hallcher and Sherman, 1980) and leads to
a decrease in the cellular concentration of myo-inositol, which can
be reversed by inositol uptake (Mustelin et al., 1986). More recently
VPA has been shown to deplete cellular inositol via inhibition of
inositol synthase (Shaltiel et al., 2004; Silverstone et al., 2002), and
CBZ to cause inositol depletion (Williams et al., 2002) by an
unknown mechanism. Finally, our recent studies indicate that
(R,S)-PIA also reduces the cellular concentrations of (InsP3)
(Shimshoni et al., 2007a). This suggests that mood stabilizers may
act via a common mechanism of suppression of inositol phosphate
based signaling, however how it affects growth conemorphology is
currently unknown.
We show here that the PIA enantiomers (S)-PIA and (R)-PIA
induce both growth cone spreading and actin polymerization, but
have no effect on TCF-mediated gene expression.We also report the
characterization of the effects of (R,S)-PIA and the mood stabilizers,
Liþ, VPA and CBZ on the growth cone cytoskeleton. We observe
a common effect of all drugs on actin cytoskeleton and an induction
of actin-rich protrusions associated with similar changes in growth
cone morphology.
2. Methods
2.1. Materials
Solvents and drugs were purchased from Sigma–Aldrich (UK). (R,S)-propyliso-
propylacetic acid (PIA) and its two enantiomers (S)-PIA and (R)-PIA were synthe-
sized according to the synthetic procedures previously described in Shimshoni et al.
(2007b). All compounds used in the in vitro experiments were dissolved in water or
ethanol to result in stock solutions of 0.2 M. Texas-Red-X phalloidin for F-actin
staining was purchased from Invitrogen, and monoclonal anti a-tubulin antibody
conjugated to FITC was obtained from Sigma–Aldrich (UK).
2.2. Dorsal root ganglion explant culture
Dorsal root ganglia (DRG) were dissected from the spinal cord of 1 day old
Sprague–Dawley rats and cultured individually on poly-ornithine/laminin coated
coverslips in serum-free medium at 37 C with 5% CO2 (Bottenstein et al., 1979).
Media were supplemented with mouse NGF-7s (25 ng/ml; the optimal concentra-
tion for growth stimulation was determined for each batch) in order to promote
neuron survival and axon outgrowth (Williams et al., 2002). After attachment for
24 h, the antimitotic agent cytosine b-arabinofuranoside (Ara-C; 10 mM) was added
for 24 h to kill non-neuronal cells. DRG explants were then changed to fresh serum-
free media for a further 24 h. Drugs were added at 2 mM NaCl (control), 2 mM LiCl,3 mM VPA, 85 mM CBZ, 1 mM (R,S)-PIA or one of its two enantiomers (S)-PIA (1 mM)
and (R)-PIA (1 mM). Mood stabilizer concentrations are 1.5 times the therapeutic
level. Time lapse video-microscopy was carried out using an IX70 inverted DIC
microscope (Olympus) at 20 magniﬁcation and recorded using an Orca ER CCD
camera (Hamamatsu) and SimplePCI v6.0 image software (Digitalpixal).
2.3. Immunocytochemistry
DRGs were washed with PBS and ﬁxed for 10 min in 4% formaldehyde. Samples
were then washed with PBS followed by 0.1% sodium borohydride and per-
meabilized in PBS solution containing 0.2% Triton X-100 and 1% BSA. Samples were
washed with PBS and blocked for 20 min in 1% BSA in PBS. Sequential staining was
carried out with a 1:400 dilution of anti-a-tubulin monoclonal antibody conjugated
to FITC for 1 h at room temperature. Samples were washed three times followed by
a 1:40 dilution of Texas-Red-X phalloidin for 20 min at room temperature. Samples
were washed with PBS and mounted with 35 ml of a mounting medium containing
antifade reagent (Vectashield Hard Set). Samples were imaged at 631.6 in oil
with simultaneous excitation at 494 nm and 596 nm, and measurement at 516 nm
for FITC and 620 nm for Texas-Red. Images were analyzed using SimplePCI v6.0
image software program and data collected using a double blind protocol. Between
10 and 50 growth cones were formed per DRG. Each experiment comprised 1–2 DRG
and was repeated in triplicate; giving between 80 and 120 growth cone measure-
ments per drug.
2.4. TCF promoter activity
Activation of TCF promoter activity was monitored using the TOPﬂash assay
(Korinek et al., 1997). HEK293 epithelial cells transfected with TCF-luciferase
reporter plasmid were seeded at 1104 cells per well of 96 well black-walled dishes
in 50 ml DMEM medium and incubated at 37 C for 48 h. Drugs were added on the
third day and cells incubated for a further 48 h. Cells were lysed in GLO lysis buffer
(Promega, Southampton, UK) and luciferase substrate (BrightGLO, Promega,
Southampton, UK) was added. Luminescence measurements were made on
a Fluostar multi-platform plate reader (BMG Labtech, Aylesbury, UK).
2.5. Statistical analysis
Analysis of growth cone morphometrics was made using a Kruskal–Wallis
analysis of variance test followed by Dunn’s multiple comparison test for post hoc
pairwise comparison with the control value. Analysis of F-actin ﬂuorescence was
made using a parametric one-way ANOVA followed by a conservative Bonferroni
Multiple Comparisons test. All statistical analyses were performed with GraphPad
InStat, version 3.01 (GraphPad Software, San Diego, CA, USA). Data are expressed as
mean S.D. A p value of 0.05 was considered signiﬁcant.
3. Results
3.1. (R,S)-PIA isomers do not induce TCF-mediated gene expression
Previous analysis indicated that unlike Liþ and VPA, (R,S)-PIA
had no effect on TCF-mediated signaling, and hence is not an
inducer of Wnt signaling. As a chiral molecule, (R,S)-PIA exists as
two enantiomers, (R)- and (S)-PIA (Fig. 1). Thus it is possible that
enantioselective activity was masked in these earlier experiments
using racemic-PIA. As the relationship between mood stabilizers
andWnt signaling is contentious, it was important to eliminate any
possibility that (R,S)-PIA could induce TCF-mediated gene expres-
sion via one of its two enantiomers.We therefore analyzedwhether
either (R)- or (S)-PIA behaved differently in a TCF-luciferase-based
reporter assay in HEK293 cells (the TOPﬂash assay). As previously
observed, Liþ induced a large (105-fold) increase in TCF-luciferase
expression, whereas VPA produced a smaller 5000-fold increase
(Fig. 2). In contrast neither CBZ, (R,S)-PIA nor the PIA enantiomers
induced an increase in TCF-luciferase expression. These results
conﬁrm that no form of PIA can induce TCF-mediated expression.
3.2. (R,S)-PIA and its two enantiomers increase growth
cone spreading
Previously Liþ, VPA, CBZ and PIA have been shown to cause
spreading of growth cones of cultured DRG neurons (Shimshoni
et al., 2007a; Williams et al., 2002). To further examine the
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Fig. 1. Chemical structures of compounds used in this study. VPA, valproic acid; (R,S)-
propylisopropylacetic acid, (R,S)-PIA; (R)-propylisopropylacetic acid, (R)-PIA; (S)-pro-
pylisopropylacetic acid, (S)-PIA; carbamazepine, CBZ.
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examined growth cone behaviour following treatment with (S)-
and (R)-PIA. Growth cones were treated with a range of drugs and
scored by measuring the spread area of each growth cone.
A signiﬁcant increase in growth cone area was observed following
treatment with 2 mM LiCl, 3 mM VPA and 85 mM CBZ. However, no
signiﬁcant increase in growth cone spreading was observed when
these concentrations were reduced. The constitutional isomer
(R,S)-PIA and its two individual enantiomers, (R)- and (S)-PIA
strongly increased growth cone spreading down to concentration
of 1 mM, signiﬁcantly lower than VPA, suggesting a higher potencyEthanol 1%
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Fig. 2. Induction of TCF-mediated gene expression. Cells were grown for 48 h in
complete medium in the presence of lithium (2 mM), CBZ (1 and 0.5 mM), VPA (3 mM),
(R,S)-PIA (1 mM) or one of its two enantiomers, (R)-PIA (1 mM) and (S)-PIA (1 mM).
The histograms show the relative light unites for the corresponding drugs assayed in
triplicates (Mean SD).of this VPA isomer than VPA itself (Fig. 3A). Again, we could observe
no difference in potency or effect between racemic-PIA and its
individual enantiomers. In all cases, addition of 2 mMmyo-inositol
reversed the drug effects, consistent with a mechanism via inositol
depletion (Fig. 3A).
To further compare the effects of each drug, we used time lapse
video-microscopy to investigate growth cone dynamics of treated
and untreated cultures (Supplementary movie). The majority of
growth cones in untreated control cultures were small and con-
tracted. They showed cycles of membrane expansion and contrac-
tion, moving forward as long projections that arise from the
relatively more spread phases of growth cone morphology.
However to make a fair comparison with the larger spread growth
cones of drug-treated cultures, we also recorded the less frequent
spread growth cones present within the untreated culture. Inter-
estingly, these growth cones remained relatively large throughout
their movement cycle and at no point did they contract to the size
of themore frequent smaller growth cones. This indicates that large
and small growth cones do not interconvert as the growth cone
moves forward. The larger growth cones were not static, instead
they showed a great deal of activity, extending and contracting both
large membranous lamellipodia and thinner ﬁlopodial-like
projections. We also noted that these larger growth cones moved
forward at a slower rate than the smaller growth cone type. For
each drug treatment, Liþ, VPA, CBZ and PIA, the growth cones
showed the same behaviour exhibited by the larger untreated
growth cones. This indicated that all drugs had the same basic
effect on growth cones, increasing the frequency of enlarged,
spread morphologies rather than causing a dramatic change in
growth cone dynamics.
3.3. Mood stabilizers alter the F-actin distribution within the
growth cone
Growth cone morphology is determined by dynamic changes of
F-actin and microtubule based cytoskeleton (Dent and Gertler,
2003). Previous studies have concentrated on the effects of mood
stabilizers on microtubule dynamics. Liþ increases microtubule
stability, causing characteristic changes inmicrotubulemorphology
(Goold et al., 1999). VPA and CBZ however do not induce an
equivalent change in microtubule morphology, instead the micro-
tubules show a splayed morphology where they leave the end of
the axon, and stain diffusely within the centre of the grow cone
(Williams et al., 2002). Given the lack of a common effect on
microtubule dynamics, we focused on changes in F-actin
distribution.
Initially, we examined global changes in F-actin content through
intensity of phalloidin staining. This was done by quantiﬁcation of
ﬂuorescence intensity of individual growth cones stained with
Texas-Red-X phalloidin (collected in the linear range) divided by
their spread area. This normalizes for the different size distribution
of treated and non-treated neurons. Liþ, VPA and CBZ had
approximately 60–70% of the F-actin content per unit area than
non-treated controls (Fig. 3B). In contrast, the F-actin content of
growth cones treated with 1 mM (R,S)-PIA (data not shown) or its
two enantiomers (Fig. 3B) was signiﬁcantly higher than those
treated with the other drugs. In fact there was no signiﬁcant
difference from the untreated control (Fig. 3B).
To understand these differences, we examined the spatial
distribution of F-actin and microtubules within growth cones
(Fig. 3C). In the majority of untreated cells F-actin forms
a predominant part of the growth cone, with rest occupied by
microtubules. However, as the untreated cells have a contracted
morphology rather than the spread morphology of those treated
with drugs, we also examined the small number of untreated
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Fig. 3. The effects of lithium, VPA, CBZ, (R,S)-PIA and its individual enantiomers (R)-PIA and (S)-PIA on growth cone morphology. (A) Histogram of the growth cone area (mm2)
(Mean SD). Grey bar, untreated control; white bar, drug treatment plus 2 mM myo-inositol. (B) Histogram of the F-actin content within growth cone, calculated as ﬂuorescence
intensity of growth cones stained with Texas-Red phalloidin normalized to growth cone area (Mean SD). (C) Representative images of growth cones double-stained with Texas-
Red phalloidin against F-actin (magenta) and with FITC-conjugated anti-a-tubulin antibody against microtubule (green). Un: untreated controls, a contracted growth cone is
shown in the main image, a spread growth cone is shown in insert; LiCl: 2 mM LiCl; VPA: 3 mM VPA; CBZ: 85 mM CBZ; PIA: 1 mM (R,S)-PIA. Bar¼ 5 mm. Sample groups comprise:
untreated control, 76 growth cones derived from 4 DRG explants; LiCl, 118 growth cones from 5 DRG explants; CBZ, 97 growth cones from 4 DRG explants; VPA, 90 growth cones
from 4 DRG explants; (R,S)-PIA, 81 growth cones from 4 DRG explants; (R)-PIA, 100 growth cones from 4 DRG explants; (S)-PIA, 81 growth cones derived from 4 DRG explants.
Signiﬁcance tests: ***p< 0.001 for experiment vs. untreated control; yyyp< 0.001 PIA species experiment vs. Liþ.
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Table 1
The number of actin-rich protrusions per growth cone.
Range Mean number
Control 0–6 2
3 mM LiCl 2–16 7
2 mM VPA 2–19 8
85 mM CBZ 2–15 6
1 mM (R,S)-PIA 0–17 6
1 mM (R)-PIA 4–17 7
1 mM (S)-PIA 1–11 5
J.A. Shimshoni et al. / Neuropharmacology 56 (2009) 831–837 835growth cones that had a large spread area. In contrast to contracted
growth cones, these showed a core region enriched in neither
F-actin nor microtubules, this central domain of growth cones is
enriched in cytoplasm, mitochondria and accumulates membrane
to facilitate extension of the axon. A similar distribution is seen in
drug-treated neurons. In these spread growth cones microtubules
were concentrated in the axon, whereas F-actinwas enriched at the
periphery of the growth cone, and only present at a low level within
the central region of the growth cone. This non-heterogeneous
distribution of F-actinwithin the growth cone caused the reduction
in F-actin polymerization when measured as total ﬂuorescence per
unit area as the largemajority of growth cones treatedwith Liþ, VPA
or CBZ had the peripheral F-actin distribution, consistent with their
larger size (Fig. 3C). This explains why these drugs caused
a decrease in average F-actin content per unit area than untreated
controls.
Examination of (R,S)-PIA (Fig. 3C), (R)-PIA or (S)-PIA (data not
shown) treated cells again showed the re-distribution of F-actin
observed with the other drugs and consistent with the spreading
effect of this drug, however the ﬂuorescence intensity within the
periphery appeared stronger. This can explain why PIA treatment
had a higher overall ﬂuorescence compared to other mood stabi-
lizers and showed no signiﬁcant reduction in overall growth cone
ﬂuorescence compared to untreated controls; i.e. the reduction of
ﬂuorescence in the central region of the (R,S)-PIA treated growth
cones is masked by elevated ﬂuorescence at the periphery.
Consistent with this we found that neurons treated with (R,S)-PIA
or its enantiomers showed signiﬁcantly more ﬂuorescence than
those treated with Liþ, VPA or CBZ (Fig. 3B). We therefore conclude
that induction of growth cones spreading following drug treatment
is coupled to alteration in actin dynamics. This effect is strongest
with (R,S)-PIA and its enantiomers, which are the most potent
drugs at inducing growth cone spreading.
3.4. Induction of F-actin-rich protrusions on the growth cone
The most striking feature of drug treatment on growth cone
morphology was the induction of F-actin-rich protrusions that
extend from both the growth cone and the axon in the vicinity
(within 65 mm) of the growth cone. These protrusions stain strongly
with Texas-Red-X phalloidin, but only weakly with a-tubulin.
There is a small degree of co-localization of F-actin and a-tubulin at
the distal ends of the protrusions, however as there is no enrich-
ment of a-tubulin compared to the central region of the growth
cone, we conclude that these structures arise through changes in
the actin cytoskeleton, rather than local generation of microtu-
bules. The protrusions observed from the proximal region of the
axon appeared to be more mixed with the majority of protrusions
enriched in F-actin, but a smaller proportion enriched in a-tubulin.
Growth cones of drug-treated neurons possessed an average of
between 5 and 8 protrusions with as many as 19 present on a single
growth cone, whilst untreated neurons possessed an average of 2
with no more than 6 present on a single growth cone (Table 1;
Fig. 4A). The increase in protrusions could arise either through
increased initiation of their formation or altered dynamics of their
growth. We observed only a small increase in protrusion length on
the growth cone and no increase on those on the axon (Fig. 4B). This
argues that although there may be some change in their growth
dynamics, the major effect of drug treatment is to increase the rate
of initiation of these F-actin structures.
4. Discussion
The identity of the cellular target of mood stabilizers remains
disputed. One argument proposes that the Wnt signaling pathwayis the important mood stabilizer target. This is supported by the
observations that Liþ inhibits GSK-3 kinase activity and causes
neuronal growth cone spreading with an associated change in
microtubule dynamics (Goold et al., 1999; Klein and Melton, 1996;
Ryves and Harwood, 2001). There is no doubt that GSK-3 is
neurologically active, as GSK-3 hypomorphic mutations and GSK-3
inhibitors cause behavioural abnormalities in mice that are similar
to those induced by treatment with antidepressant drugs (Beaulieu
et al., 2004; Gould et al., 2004; Kaidanovich-Beilin et al., 2004;
O’Brien et al., 2004). GSK-3 mediated signaling is also involved in
mechanisms of neuroprotection and has been associated with
schizophrenia (Lovestone et al., 2007; Toledo et al., 2008). However,
there is currently no direct evidence to link GSK-3 to bipolar mood
disorder. On the other hand, the less commonly used mood stabi-
lizer CBZ also causes growth cone spreading, but with no change in
microtubule structure or inhibition of GSK-3. CBZ has previously
been shown to have no effect on b-catenin expression (Ryves et al.,
2005), and we show here that CBZ does not induce TCF-mediated
gene expression, eliminating any possibility of a b-catenin inde-
pendent mechanism of stimulating Wnt signaling.
The situationwith VPA is less clear. Initial reports suggested that
VPA may directly inhibit GSK-3 (Chen et al., 1999), however
a number of further investigations have demonstrated this not to be
the case (Eickholt et al., 2005; Phiel et al., 2001; Ryves et al., 2005).
VPA has been shown to alter gene expression via inhibition of
histone deacetyalses (HDACs), and, in some but not all, cell contexts
VPA can induce expression of b-catenin leading to stimulation of
TCF-mediated gene expression (Phiel et al., 2001; Ryves et al.,
2005). Previous reports, and those reported here, show that the
effect of VPA on growth cone morphology is like that of CBZ (Wil-
liams et al., 2002) and, with the exception of one report (Hall et al.,
2002), VPA and CBZ were shown to cause growth cone spreading
without a change in microtubule dynamics. The VPA isomer (R,S)-
PIA again has no effect on HDAC activity and only weak antiepi-
leptic activity, but is a potent inducer of growth cone spreading
(Shimshoni et al., 2007a). We can now exclude the possibility that
an enantiomer speciﬁc effect on TCF-mediated gene expressionwas
missed in this earlier experiment, and can conclude without doubt
that the VPA constitutional isomer (R,S)-PIA can induce growth
cone spreading without activation of Wnt signaling. It remains to
be seen how (R,S)-PIA performs in animal models of bipolar
disorder or patients.
To understand how the mood stabilizers, Liþ, VPA and CBZ, and
(R,S)-PIA cause changes in growth cone morphology, we examined
underlying changes in the actin cytoskeleton. We found two effects
common to all drugs. First, we found that growth cone spreading is
associated with localization of F-actin to the periphery of the cone.
This is a feature of all spread growth cones, including those of the
few observed in untreated control. Both qualitative examination of
images and quantitative measurements of the intensity of phal-
loidin staining indicated that (R,S)-PIA induces elevated levels of
F-actin. As (R,S)-PIA exhibits its effects at a lower concentration
than VPA and therefore is the most potent inducer of growth cone
spreading, these results suggest that drug treatment can drive local
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Fig. 4. The effects of lithium, VPA, CBZ, (R,S)-PIA and its two individual enantiomers (R)-PIA and (S)-PIA on actin-rich protrusions. (A) Histogram to show the mean (SD) number of
F-actin-rich protrusions per growth cone (dark bars) or along an axonal section close to (<65 mm) the growth cone (light bar). (B) Histogram to showmean length of the protrusions
extending from the growth cone or an axonal section close to (<65 mm) the growth cone (light bar). Sample groups comprise: untreated controls, 76 growth cones from 4 DRG
explants; 2 mM LiCl, 118 growth cones from 5 DRG explants; 85 mM CBZ, 97 growth cones from 4 DRG explants; 3 mM VPA, 90 growth cones from 4 DRG explants; 1 mM (R,S)-PIA,
81 growth cones from 4 DRG explants; 1 mM (R)-PIA, 100 growth cones from 4 DRG explants; 1 mM (S)-PIA, 81 growth cones from 4 DRG explants. Total data were analyzed by
a Kruskal–Wallis test, followed by Dunn’s multiple comparison test of each experiment vs. control: *p< 0.05; **p< 0.01; ***p< 0.001.
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morphology.
Second, we ﬁnd that all drugs induce a substantial increase in
F-actin enriched protrusions that extend from the growth cone or
its close vicinity. They are present at a low frequency on untreated
DRG neurons, and as there is only a marginal increase in length, but
a large increase in number following drug treatment, we conclude
that mood stabilizers induce formation of these protrusions rather
than have amajor effect on the stability of those already extant. The
morphology, restricted distribution and lack of a-tubulin enrich-
ment indicate that these structures are not the same as the inter-
stitial branching previously observed following Liþ, but not VPA and
CBZ treatment (Williams et al., 2002). As they are longer than 2 mm
and enriched in F-actin, they resemble ﬁlopodia located on the
axonal growth cone, which forms at the leading edge of motile cells
or during early stages of synaptogenesis (Waites et al., 2005).
However, unlike reports for ﬁlopodia, they can branch and in places
become thickened. As a consequence the actual identity of these
protrusions is unclear. Their presence does however indicate that
(R,S)-PIA and mood stabilizers have a substantial effect on the
neuronal actin-based cytoskeleton.
As enlarged growth cones are observed on presynaptic termi-
nals during synaptogenesis, axon bifurcation and during periods of
sensing guidance cues from the environment (Eickholt et al., 2004;
Williams et al., 2004), these ﬁndings support the hypothesis that
mood stabilizers modify the neural architecture. Such changes
could lead to increased local neuronal interactions and connec-
tivity, thereby reversing the reduced neuronal density observed in
bipolar patients (Adler et al., 2005). This could occur via the longer-
term events of neuronal morphogenesis. Alternatively functional
changes could have more immediate effects on synapse function of
the presynaptic terminal and structural plasticity (Luo, 2002).
Although the actin cytoskeleton is not essential for axonal
elongation, it is an important component of growth cone guidance.
One possibility is that mood stabilizers alter responses to extra-
cellular signals leading to a change in the network of neuronal
interactions. This re-wiring could occur during periods of neuronal
development, including the establishment of new neuronal inter-
actions following neurogenesis. Indeed several studies have
demonstrated a reversal of the reduction in grey matter volume in
the prefrontal cortex and an increased neuronal and glial density,
following treatment with mood stabilizers (Frey et al., 2004, 2007).
On a faster timescale, regulation of actin polymerization is alsoimportant for synapse formation of pre- and post-synaptic termi-
nals, controlling both remodeling of the post-synaptic membrane
and vesicle transport and the movement of dendritic spines, which
form the majority of the post-synaptic sites within the mammalian
brain. It is possible that drug-mediated changes in actin dynamics
may alter the processes governing synapse formation of pre- and
post-synaptic terminals, stability or function. Finally, as ﬁlopod
formation is an early stage of synaptogenesis of presynaptic
terminals, the increase in actin-rich protrusions observed in drug-
treated growth cones may reﬂect a switch from axonal growth to
synapse formation.
In conclusion, this study using (R,S)-PIA, its individual enan-
tiomers and mood stabilizers further indicates a Wnt independent
change in neuronal behaviour. In contrast to earlier work that
focused on the effects of Liþ on microtubule dynamics, this current
study argues for a common effect for mood stabilizers on the actin
cytoskeleton, which may lead to changes in neuronal morphology
and plasticity in the CNS. (R,S)-PIA and its individual enantiomers
are potent inducers of this effect, and suggest their potential as new
mood stabilizers.
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